Myocarditis medical therapy

Myocarditis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Adrenergic Myocarditis
Giant Cell Myocarditis

Causes

Differentiating Myocarditis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myocarditis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Google Images

American Roentgen Ray Society Images of Myocarditis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myocarditis medical therapy

CDC on Myocarditis medical therapy

Myocarditis medical therapy in the news

Blogs on Myocarditis medical therapy

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Myocarditis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:  Varun Kumar, M.B.B.S.; Maliha Shakil, M.D. [2] Homa Najafi, M.D.[3]

## Overview[edit | edit source]

Symptomatic treatment is the mainstay of therapy for patients with viral myocarditis. Supportive therapy includes diuretics and inotropes for left ventricular failure. ACE inhibitor therapy may aid in left ventricular remodeling. Among patients with fulminant myocarditis, placement of either an intra-aortic balloon pump or a left ventricular assist device may be necessary as bridge to recovery. Administration of antimicrobial therapy is recommended for bacterial myocarditis. Immunosuppressive therapy may be effective in the management of giant cell myocarditis, autoimmune myocarditis, and eosinophilic myocarditis. In patients with arrythmias, treatment should be initiated only if arrhythmias are symptomatic or sustained. Myocarditis patients presenting with conduction abnormalities, particularly Mobitz type II and complete heart block require temporary pacemaker usually during the acute phase.

## Medical Therapy[edit | edit source]

### Lymphocytic/Viral Myocarditis[edit | edit source]

* The mainstay of therapy for viral myocarditis is supportive care and standard management of CHF.[1][2][3][4][5][6][5][7] [8][9][10][11][12][13][14][15][16][17][18]
* The Heart Failure Society of America recommends against the routine use of immunosuppressive agents in treatment of myocarditis.

* Animal studies have demonstrated better outcomes in viral myocarditis with the use of antiviral agents and interferon early in the course of infection prior to inoculation. The use of antiviral therapy may be limited since patients with viral myocarditis are usually not seen in the early stages. However, it may be used in acute, fulminant myocarditis and in institutional outbreaks. In a series, 6 months of beta interferon in patients with myocarditis secondary to enterovirus or adenovirus infection resulted in the elimination of viral genomes in all patients and improvement of LV function in 68% of the patients.

* Immunotherapy was thought to be a treatment option for myocarditis as they suppress the activity of immunologic agents mediating myocardial inflammation. There is no significant change in mortality rate with immunotherapy. However, improvement in LV function is seen in patients with chronic inflammatory dilated cardiomyopathy.

* Intravenous immunoglobulin (IVIG) is known to have both antiviral and immunologic properties. Therefore, it can be used in both viral and autoimmune types of myocarditis.
* Temporary pacemaker insertion is indicated in patients with symptomatic bradycardia and/or heart block during the acute phase of myocarditis.
* ICD implantation is not indicated during the acute phase of myocarditis.
* Antiarrhythmic therapy can be useful in patients with symptomatic NSVT or sustained VT during the acute phase of myocarditis.

### Giant Cell Myocarditis[edit | edit source]

* Giant cell myocarditis is a rare form of myocarditis and is generally associated with a poor prognosis. In a non-randomized series, 22 patients with giant cell myocarditis who were treated with corticosteroids and cyclosporine/azathioprine, survived for an average of 12.3 months. In contrast, those patients who were not treated with immunosuppressants survived for an average of 3 months. Use of immunosuppressive therapy was further strengthened by a prospective, multicenter observational study which reported an improved survival of 6 years among patients receiving high dose steroids and cyclosporine with or without muromonab-CD3. Of the 11 patients studied, two patients underwent cardiac transplantation early in the course of the study and one patient died. The study also reported that withdrawal of immunosuppression was associated with a recurrence of giant cell myocarditis in some patients which in some cases was fatal. Immunosuppressive therapy directed at T-cells may be beneficial as T-cells mediate myocardial inflammation.[19][20][21]

* Cardiac transplantation is sometimes required to treat refractory giant cell myocarditis. However, the condition can recur in post-transplant patients. Recurrence of biopsy proven giant cell myocarditis between 3 weeks to 9 years was observed in 9 of 34 cardiac transplant patients.

### Eosinophilic Myocarditis[edit | edit source]

* Eosinophilic myocarditis can occur secondary to hypersensitivity to drugs, parasitic infestation, or hypereosinophilic syndrome. The eosinophils which infiltrate the myocardium, degenerate leading to extracellular release of eosinophil granules which can contribute to death of myocytes. Usage of immunosuppressants such as high dose steroids (after excluding infections) and removal of offending drug (in drug induced hypersensitivity) is known to be beneficial in treatment of eosinophilic myocarditis. Immunosuppressive therapy may be tapered gradually after one year if normal cardiac function and cardiac enzymes levels are restored.[22][23]

### Autoimmune Myocarditis[edit | edit source]

* Myocarditis can develop in autoimmune diseases such as celiac disease and sarcoidosis. Treatment with gluten-free diet and immunosuppressants in celiac disease improves cardiac function. Corticosteroids are found to be beneficial in patients with sarcoidosis related myocarditis, particularly during initial stages of the disease before development of extensive fibrosis of myocardium.[24][25]

## Treatment of Heart Failure[edit | edit source]

* As heart failure in patients with myocarditis has poor prognosis, it is important to prevent progression or worsening of cardiac dysfunction. These patients should be treated with low sodium intake, diuretics and ACE inhibitors. Few animal studies report that mortality rate is high with digoxin in comparison to beta blocker in viral myocarditis. Studies have also demonstrated that usage of carvedilol during recovery phase decreases expression of several histochemicals and subsequently myocardial inflammation and there by improving survival. The beta-blockers should however be avoided in the acutely decompensating phase of illness. If heart failure or cardiogenic shock does not respond to medical therapy, circulatory support with an intraaortic balloon pump should be considered which could be used in fulminant myocarditis as a bridge to spontaneous recovery. Implantation of ICD in severe heart failure should be deferred for several months to allow sufficient time for recovery of ventricular function. Following the initial circulatory stabilization, further treatment of cardiac dysfunction should follow current ACC/AHA recommendations. Anticoagulation may be considered in patients with severe/chronic heart failure as they are at risk for developing thromboembolic complications.[26][27][28][29][30][31][32]

* For more information on heart failure treatment, click here.

## Treatment of Arrhythmia[edit | edit source]

* Arrhythmias or conduction abnormalities can occur in patients with myocarditis. Treatment should be initiated only if arrhythmias are symptomatic or sustained. Caution should be observed while using antiarrhythmics as majority of these agents have negative inotropic property which may worsen heart failure. Regular monitoring with ECG is important as it enables early detection and treatment of asymptomatic yet life threatening arrhythmias.
* Supraventricular tachycardia (SVT) can aggravate heart failure. Symptomatic and sustained SVT should be immediately converted electrically. While, patients with recurrent sustained SVT should be treated with antiarrhythmics and rate controlling agents. Implantation of ICD should be considered in patients with recurrent ventricular arrhythmia refractory to medical therapy. Myocarditis patients presenting with conduction abnormalities, particularly Mobitz type II and complete heart block require temporary pacemaker usually during the acute phase. Implantation of permanent pacemaker or ICD may be necessary in few patients.[33]

## 2006 ACC/AHA/ESC Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death - Myocarditis, Rheumatic Disease, and Endocarditis[34][edit | edit source]

Class I

1. Temporary pacemaker insertion is indicated in patients with symptomatic bradycardia and/or heart block during the acute phase of myocarditis. (Level of Evidence: C)
2. Acute aortic regurgitation associated with VT should be treated surgically unless otherwise contraindicated.(Level of Evidence: C)
3. Acute endocarditis complicated by aortic or annular abscess and AV block should be treated surgically unless otherwise contraindicated. (Level of Evidence: C)
Class III

1.ICD implantation is not indicated during the acute phase of myocarditis. (Level of Evidence: C)
Class IIa

1. ICD implantation can be beneﬁcial in patients with life-threatening ventricular arrhythmias who are not in the acute phase of myocarditis, as indicated in the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmic devices who are receiving chronic optimal medical therapy, and who have reasonable expectation of survival with a good functional status for more than 1 year. (Level of Evidence: C)[35]
2. Antiarrhythmic therapy can be useful in patients with symptomatic NSVT or sustained VT during the acute phase of myocarditis. (Level of Evidence: C)

## 2013 ESC Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death - Myocarditis, Rheumatic Disease, and Endocarditis[36][edit | edit source]

Class I

1. It is recommended that patients with a life-threatening presentation of sustained ventricular tachyarrhythmias in the context of clinically suspected myocarditis are referred to specialized centers with the ability to perform hemodynamic monitoring, cardiac catheterization and endomyocardial biopsy and to use mechanical cardio-pulmonary assist devices and specialized arrhythmia therapies. (Level of Evidence: C)[37][38][39][40]
2. Temporary pacemaker insertion is recommended in patients with bradycardia and/or heart block triggering VA during the acute phase of myocarditis/pancarditis.(Level of Evidence: C)[37][41]
Class IIa

1.Anti-arrhythmic therapy should be considered in patients with symptomatic non-sustained or sustained VT during the acute phase of myocarditis.(Level of Evidence: C)[37]
2. The implant of an ICD or pacemaker in patients with inflammatory heart diseases should be considered after resolution of the acute episode. (Level of Evidence: C)[37][42]
3. In patients with hemodynamically compromising sustained VT occurring after the resolution of acute episodes, an ICD implantation should be considered if the patient is expected to survive >1 year with good functional status. (Level of Evidence: C)
4. A wearable defibrillator should be considered for bridging until full recovery or ICD implantation in patients after inflammatory heart diseases with residual severe LV dysfunction and/or ventricular electrical instability. (Level of Evidence: C)[43][44]
Class IIb

1. ICD implantation may be considered earlier in patients with giant cell myocarditis or sarcoidosis who had hemodynamically compromising sustained VA or aborted cardiac arrest, due to adverse prognosis of these conditions, if survival >1 year with good functional status can be expected. (Level of Evidence: C)[45]
2. Demonstration of persistent myocardial inflammatory infiltrates by immunohistological evidence and/or abnormal localized fibrosis by CMR after acute myocarditis may be considered as an additional indicator of increased risk of SCD in inflammatory heart disease. (Level of Evidence: C)[46]

## References[edit | edit source]

1. ↑ Kishimoto C, Crumpacker CS, Abelmann WH (1988). "Prevention of murine coxsackie B3 viral myocarditis and associated lymphoid organ atrophy with recombinant human leucocyte interferon alpha A/D". Cardiovasc Res. 22 (10): 732–8. PMID 2855719.CS1 maint: Multiple names: authors list (link)
2. ↑ Yamamoto N, Shibamori M, Ogura M, Seko Y, Kikuchi M (1998). "Effects of intranasal administration of recombinant murine interferon-gamma on murine acute myocarditis caused by encephalomyocarditis virus". Circulation. 97 (10): 1017–23. PMID 9529271.CS1 maint: Multiple names: authors list (link)
3. ↑ Ray CG, Icenogle TB, Minnich LL, Copeland JG, Grogan TM (1989). "The use of intravenous ribavirin to treat influenza virus-associated acute myocarditis". J Infect Dis. 159 (5): 829–36. PMID 2775346.CS1 maint: Multiple names: authors list (link)
4. ↑ Kühl U, Pauschinger M, Schwimmbeck PL, Seeberg B, Lober C, Noutsias M; et al. (2003). "Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction". Circulation. 107 (22): 2793–8. doi:10.1161/01.CIR.0000072766.67150.51. PMID 12771005. Unknown parameter `|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=` ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
5. ↑ 5.0 5.1 Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, Glanowska G, Wilczewski P, Niklewski T; et al. (2001). "Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results". Circulation. 104 (1): 39–45. PMID 11435335.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
6. ↑ Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME; et al. (1995). "A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators". N Engl J Med. 333 (5): 269–75. doi:10.1056/NEJM199508033330501. PMID 7596370.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
7. ↑ Frustaci A, Russo MA, Chimenti C (2009). "Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study". Eur Heart J. 30 (16): 1995–2002. doi:10.1093/eurheartj/ehp249. PMID 19556262. Unknown parameter `|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=` ignored (help)CS1 maint: Multiple names: authors list (link)
8. ↑
9. ↑ McNamara DM, Holubkov R, Starling RC, Dec GW, Loh E, Torre-Amione G; et al. (2001). "Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy". Circulation. 103 (18): 2254–9. PMID 11342473.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
10. ↑ Shioji K, Matsuura Y, Iwase T, Kitaguchi S, Nakamura H, Yodoi J; et al. (2002). "Successful immunoglobulin treatment for fulminant myocarditis and serial analysis of serum thioredoxin: a case report". Circ J. 66 (10): 977–80. PMID 12381097.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
11. ↑ Takeda Y, Yasuda S, Miyazaki S, Daikoku S, Nakatani S, Nonogi H (1998). "High-dose immunoglobulin G therapy for fulminant myocarditis". Jpn Circ J. 62 (11): 871–2. PMID 9856608.CS1 maint: Multiple names: authors list (link)
12. ↑ McNamara DM, Rosenblum WD, Janosko KM, Trost MK, Villaneuva FS, Demetris AJ; et al. (1997). "Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy". Circulation. 95 (11): 2476–8. PMID 9184576.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
13. ↑ Kim HS, Sohn S, Park JY, Seo JW (2004). "Fulminant myocarditis successfully treated with high-dose immunoglobulin". Int J Cardiol. 96 (3): 485–6. doi:10.1016/j.ijcard.2003.05.037. PMID 15301907. Unknown parameter `|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=` ignored (help)CS1 maint: Multiple names: authors list (link)
14. ↑ Drucker NA, Colan SD, Lewis AB, Beiser AS, Wessel DL, Takahashi M; et al. (1994). "Gamma-globulin treatment of acute myocarditis in the pediatric population". Circulation. 89 (1): 252–7. PMID 8281654.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
15. ↑ Meune C, Spaulding C, Mahé I, Lebon P, Bergmann JF (2003). "Risks versus benefits of NSAIDs including aspirin in myocarditis: a review of the evidence from animal studies". Drug Saf. 26 (13): 975–81. PMID 14583071. Unknown parameter `|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=` ignored (help)CS1 maint: Multiple names: authors list (link)
16. ↑ Imazio M, Trinchero R (2008). "Myopericarditis: Etiology, management, and prognosis". Int J Cardiol. 127 (1): 17–26. doi:10.1016/j.ijcard.2007.10.053. PMID 18221804. Unknown parameter `|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=` ignored (help)
17. ↑ Khatib R, Reyes MP, Smith F, Khatib G, Rezkalla S (1990). "Enhancement of coxsackievirus B4 virulence by indomethacin". J Lab Clin Med. 116 (1): 116–20. PMID 1695914.CS1 maint: Multiple names: authors list (link)
18. ↑ Rezkalla S, Khatib G, Khatib R (1986). "Coxsackievirus B3 murine myocarditis: deleterious effects of nonsteroidal anti-inflammatory agents". J Lab Clin Med. 107 (4): 393–5. PMID 2420912. Unknown parameter `|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=` ignored (help)CS1 maint: Multiple names: authors list (link)
19. ↑ Menghini VV, Savcenko V, Olson LJ, Tazelaar HD, Dec GW, Kao A; et al. (1999). "Combined immunosuppression for the treatment of idiopathic giant cell myocarditis". Mayo Clin Proc. 74 (12): 1221–6. PMID 10593350.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
20. ↑ Cooper LT, Berry GJ, Shabetai R (1997). "Idiopathic giant-cell myocarditis--natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators". N Engl J Med. 336 (26): 1860–6. doi:10.1056/NEJM199706263362603. PMID 9197214.CS1 maint: Multiple names: authors list (link)
21. ↑ Cooper LT, Hare JM, Tazelaar HD, Edwards WD, Starling RC, Deng MC; et al. (2008). "Usefulness of immunosuppression for giant cell myocarditis". Am J Cardiol. 102 (11): 1535–9. doi:10.1016/j.amjcard.2008.07.041. PMC 2613862. PMID 19026310.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link) CS1 maint: PMC format (link)
22. ↑ Cooper LT, Zehr KJ (2005). "Biventricular assist device placement and immunosuppression as therapy for necrotizing eosinophilic myocarditis". Nat Clin Pract Cardiovasc Med. 2 (10): 544–8. doi:10.1038/ncpcardio0322. PMID 16186853. Unknown parameter `|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=` ignored (help)
23. ↑ Corradi D, Vaglio A, Maestri R, Legname V, Leonardi G, Bartoloni G; et al. (2004). "Eosinophilic myocarditis in a patient with idiopathic hypereosinophilic syndrome: insights into mechanisms of myocardial cell death". Hum Pathol. 35 (9): 1160–3. PMID 15343520. Unknown parameter `|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=` ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
24. ↑ Kim JS, Judson MA, Donnino R, Gold M, Cooper LT, Prystowsky EN; et al. (2009). "Cardiac sarcoidosis". Am Heart J. 157 (1): 9–21. doi:10.1016/j.ahj.2008.09.009. PMID 19081391. Unknown parameter `|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=` ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
25. ↑ Frustaci A, Cuoco L, Chimenti C, Pieroni M, Fioravanti G, Gentiloni N; et al. (2002). "Celiac disease associated with autoimmune myocarditis". Circulation. 105 (22): 2611–8. PMID 12045166.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
26. ↑ Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG; et al. (2009). "2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation". Circulation. 119 (14): e391–479. doi:10.1161/CIRCULATIONAHA.109.192065. PMID 19324966. Unknown parameter `|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=` ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
27. ↑ Magnani JW, Danik HJ, Dec GW, DiSalvo TG (2006). "Survival in biopsy-proven myocarditis: a long-term retrospective analysis of the histopathologic, clinical, and hemodynamic predictors". Am Heart J. 151 (2): 463–70. doi:10.1016/j.ahj.2005.03.037. PMID 16442915. Unknown parameter `|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=` ignored (help)CS1 maint: Multiple names: authors list (link)
28. ↑ Tominaga M, Matsumori A, Okada I, Yamada T, Kawai C (1991). "Beta-blocker treatment of dilated cardiomyopathy. Beneficial effect of carteolol in mice". Circulation. 83 (6): 2021–8. PMID 1674900.CS1 maint: Multiple names: authors list (link)
29. ↑ Matsumori A, Igata H, Ono K, Iwasaki A, Miyamoto T, Nishio R; et al. (1999). "High doses of digitalis increase the myocardial production of proinflammatory cytokines and worsen myocardial injury in viral myocarditis: a possible mechanism of digitalis toxicity". Jpn Circ J. 63 (12): 934–40. PMID 10614837.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
30. ↑ Wang JF, Meissner A, Malek S, Chen Y, Ke Q, Zhang J; et al. (2005). "Propranolol ameliorates and epinephrine exacerbates progression of acute and chronic viral myocarditis". Am J Physiol Heart Circ Physiol. 289 (4): H1577–83. doi:10.1152/ajpheart.00258.2005. PMID 15923319. Unknown parameter `|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=` ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
31. ↑ Rockman HA, Adamson RM, Dembitsky WP, Bonar JW, Jaski BE (1991). "Acute fulminant myocarditis: long-term follow-up after circulatory support with left ventricular assist device". Am Heart J. 121 (3 Pt 1): 922–6. PMID 2000764.CS1 maint: Multiple names: authors list (link)
32. ↑ Chen JM, Spanier TB, Gonzalez JJ, Marelli D, Flannery MA, Tector KA; et al. (1999). "Improved survival in patients with acute myocarditis using external pulsatile mechanical ventricular assistance". J Heart Lung Transplant. 18 (4): 351–7. PMID 10226900. Unknown parameter `|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=` ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
33. ↑ Cooper LT (2009). "Myocarditis". N Engl J Med. 360 (15): 1526–38. doi:10.1056/NEJMra0800028. PMID 19357408. Unknown parameter `|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=` ignored (help)
34. ↑ European Heart Rhythm Association. Heart Rhythm Society. Zipes DP, Camm AJ, Borggrefe M, Buxton AE; et al. (2006). "ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death)". J Am Coll Cardiol. 48 (5): e247–346. doi:10.1016/j.jacc.2006.07.010. PMID 16949478. Unknown parameter `|http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=` ignored (help)CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
35. ↑ Gregoratos G, Abrams J, Epstein AE, Freedman RA, Hayes DL, Hlatky MA; et al. (2002). "ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines)". Circulation. 106 (16): 2145–61. PMID 12379588.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
36. ↑ Priori, Silvia G.; Blomström-Lundqvist, Carina; Mazzanti, Andrea; Blom, Nico; Borggrefe, Martin; Camm, John; Elliott, Perry Mark; Fitzsimons, Donna; Hatala, Robert; Hindricks, Gerhard; Kirchhof, Paulus; Kjeldsen, Keld; Kuck, Karl-Heinz; Hernandez-Madrid, Antonio; Nikolaou, Nikolaos; Norekvål, Tone M.; Spaulding, Christian; Van Veldhuisen, Dirk J. (2015). "2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death". European Heart Journal. 36 (41): 2793–2867. doi:10.1093/eurheartj/ehv316. ISSN 0195-668X.
37. ↑ 37.0 37.1 37.2 37.3 Caforio, A. L. P.; Pankuweit, S.; Arbustini, E.; Basso, C.; Gimeno-Blanes, J.; Felix, S. B.; Fu, M.; Helio, T.; Heymans, S.; Jahns, R.; Klingel, K.; Linhart, A.; Maisch, B.; McKenna, W.; Mogensen, J.; Pinto, Y. M.; Ristic, A.; Schultheiss, H.-P.; Seggewiss, H.; Tavazzi, L.; Thiene, G.; Yilmaz, A.; Charron, P.; Elliott, P. M. (2013). "Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases". European Heart Journal. 34 (33): 2636–2648. doi:10.1093/eurheartj/eht210. ISSN 0195-668X.
38. ↑ "Guidelines for diagnosis and treatment of myocarditis (JCS 2009): digest version". Circulation journal : official journal of the Japanese Circulation Society. 75 (3): 734–743. 2011. doi:10.1253/circj.cj-88-0008. PMID 21304213.
39. ↑ Naoyoshi Aoyama, Tohru Izumi, Katsuhiko Hiramori, Mitsuaki Isobe, Masatoshi Kawana, Michiaki Hiroe, Hitoshi Hishida, Yasushi Kitaura & Tsutomu Imaizumi (2002). "National survey of fulminant myocarditis in Japan: therapeutic guidelines and long-term prognosis of using percutaneous cardiopulmonary support for fulminant myocarditis (special report from a scientific committee)". Circulation journal : official journal of the Japanese Circulation Society. 66 (2): 133–144. doi:10.1253/circj.66.133. PMID 11999637. Unknown parameter `|month=` ignored (help)CS1 maint: Multiple names: authors list (link)
40. ↑ Liberman, Leonardo; Anderson, Brett; Silver, Eric S.; Singh, Rakesh; Richmond, Marc E. (2014). "INCIDENCE AND CHARACTERISTICS OF ARRHYTHMIAS IN PEDIATRIC PATIENTS WITH MYOCARDITIS: A MULTICENTER STUDY". Journal of the American College of Cardiology. 63 (12): A483. doi:10.1016/S0735-1097(14)60483-6. ISSN 0735-1097.
41. ↑ "Guidelines for diagnosis and treatment of myocarditis (JCS 2009): digest version". Circulation journal : official journal of the Japanese Circulation Society. 75 (3): 734–743. 2011. doi:10.1253/circj.cj-88-0008. PMID 21304213.
42. ↑ Kindermann, Ingrid; Kindermann, Michael; Kandolf, Reinhard; Klingel, Karin; Bültmann, Burkhard; Müller, Thomas; Lindinger, Angelika; Böhm, Michael (2008). "Predictors of Outcome in Patients With Suspected Myocarditis". Circulation. 118 (6): 639–648. doi:10.1161/CIRCULATIONAHA.108.769489. ISSN 0009-7322.
43. ↑ Prochnau, Dirk; Surber, Ralf; Kuehnert, Helmut; Heinke, Matthias; Klein, Helmut U.; Figulla, Hans R. (2009). "Successful use of a wearable cardioverter-defibrillator in myocarditis with normal ejection fraction". Clinical Research in Cardiology. 99 (2): 129–131. doi:10.1007/s00392-009-0093-2. ISSN 1861-0684.
44. ↑ Chung, Mina K. (2014). "The Role of the Wearable Cardioverter Defibrillator in Clinical Practice". Cardiology Clinics. 32 (2): 253–270. doi:10.1016/j.ccl.2013.11.002. ISSN 0733-8651.
45. ↑ Kandolin, Riina; Lehtonen, Jukka; Salmenkivi, Kaisa; Räisänen-Sokolowski, Anne; Lommi, Jyri; Kupari, Markku (2013). "Diagnosis, Treatment, and Outcome of Giant-Cell Myocarditis in the Era of Combined Immunosuppression". Circulation: Heart Failure. 6 (1): 15–22. doi:10.1161/CIRCHEARTFAILURE.112.969261. ISSN 1941-3289.
46. ↑ Schumm, Julia; Greulich, Simon; Wagner, Anja; Grün, Stefan; Ong, Peter; Bentz, Kerstin; Klingel, Karin; Kandolf, Reinhard; Bruder, Oliver; Schneider, Steffen; Sechtem, Udo; Mahrholdt, Heiko (2014). "Cardiovascular magnetic resonance risk stratification in patients with clinically suspected myocarditis". Journal of Cardiovascular Magnetic Resonance. 16 (1): 14. doi:10.1186/1532-429X-16-14. ISSN 1532-429X.

Template:WH Template:WS